Recombinant interleukin-2-based treatments for advanced melanoma: The experience of the european organization for research and treatment of cancer melanoma cooperative group

Cancer Journal from Scientific American

Volumn 3, Issue SUPPL. 1, 1997, Pages

  Keilholz, Ulrich ^a   Stoter, Gerrit ^b   Punt, Cornelis J A ^c   Scheibenbogen, Carmen ^a   Lejeune, Ferdy ^d   Eggermont, Alexander M M ^b  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b ERASMUS MEDICAL CENTER   (Netherlands)

^c RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^d Ctr Pluridisciplinaire d'Oncologie   (Switzerland)

Author keywords

Immunotherapy; Interferon ; Interteukin 2; Melanoma

Indexed keywords

ALPHA INTERFERON; CARMUSTINE; CISPLATIN; DACARBAZINE; LACTATE DEHYDROGENASE; RECOMBINANT INTERLEUKIN 2; T LYMPHOCYTE RECEPTOR; TAMOXIFEN;

ADVANCED CANCER; ARTICLE; BOLUS INJECTION; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; CONTINUOUS INFUSION; CONTROLLED STUDY; DRUG EFFICACY; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LACTATE DEHYDROGENASE BLOOD LEVEL; MELANOMA; MULTICENTER STUDY; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; CLINICAL TRIALS; DACARBAZINE; HUMANS; IMMUNOTHERAPY; INTERFERON-ALPHA; INTERLEUKIN-2; MELANOMA; RECOMBINANT PROTEINS; SURVIVAL RATE;

EID: 0031406876     PISSN: 10814442     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (62)

1. Seigler HF, Lucas VS, Picett NJ et al. DTIC, CCNU, bleomycin, and vincristine (BOLD) in metastatic melanoma. Cancer 1980; 46:2346-2348.
2. Legha S. Current therapy for malignant melanoma. Semin Oncol 1989;16:34-44.
3. Lakhani S, Selby P, Bliss JM et al. Chemotherapy for malignant melanoma: combinations and high doses produce more responses without survival benefit. Br J Cancer 1990;61:330-334.
4. Balch CM. Cutaneous melanoma: prognosis and treatment results worldwide. Semin Surg Oncol 1992;8:400-414.
5. Cocconi G, Bella M, Calabresi F et al. Treatment of metastatic malignant melanoma with dacarbazine plus tamoxifen. N Engl J Med 1992;327:516-523.
6. Falkson CL, Falkson G, Falkson HC. Improved results with the addition of interferon alfa-2b to dacarbazine in the treatment of patients with metastatic malignant melanoma. J Clin Oncol 1991;9: 1403-1408.
7. Falkson CL, Ibrahim J, Kirkwood J et al. A randomized phase III trial of dacarbazine (DTIC) versus DTIC + interferon alfa 2b versus DTIC + tamoxifen (TMX) versus DTIC + IFN + TMX in metastatic malignant melanoma: an ECOG trial [abstract]. Proceedings of ASCO 1996;15:435.
8. Thompson DB, Adena M, McLeod GR et al. Interferon-alfa 2a does not improve response or survival when combined with dacarbazine in metastatic malignant melanoma: results of a multi-institutional Australian randomized trial. Melanoma Res 1993;3:133-138.
9. Bajetta E, Di Leo A, Zampino MG et al. Multicenter randomized trial of dacarbazine alone or in combination of two different doses and schedules of interferon alfa-2a in the treatment of advanced melanoma. J Clin Oncol 1994;12:806-811.
10. Rusthoven JJ, Quirt IC, Iscoe NA et al. Randomized, double-blind, placebo controlled trial comparing the response rates of carmustine, dacarbazine, and cisplatin with and without tamoxifen in patients with metastatic melanoma. J Clin Oncol 1996;14:2083-2090.
11. Cox AL, Skipper J, Chen Y et al. Identification of a peptide recognized by five melanoma-specific human cytotoxic T cell lines. Science 1994;264:716-719.
12. Rivoltini L, Kawakami Y, Sakaguchi K et al. Induction of tumor-reactive CTL from peripheral blood and tumor-infiltrating lymphocytes of melanoma patients by in vitro stimulation with an immunodominant peptide of the human melanoma antigen MART-1. J Immunol 1995;154:2257-2265.
13. Wölfel T, Van Pel A, Brichard V et al. Two tyrosinase nonapeptides recognized on HLA-A2 melanomas by autologous cytolytic T lymphocytes. Eur J Immunol 1994;24:759-764.
14. Marincola FM, Rivoltini L, Salgaller ML et al. Differential anti-MART-1/Melan A CTL activity in peripheral blood of HLA-A2 melanoma patients in comparison to healthy donors: evidence for in vivo priming by tumor cells. J Immunother Emphasis Tumor Immunol 1996;19:266-277.
15. Puisieux I, Even J, Pannetier C et al. Oligoclonality of tumor-infiltrating lymphocytes from human melanomas. J Immunol 1994; 153:2807-2818.
16. Mohler T, Willhauck M, Scheibenbogen C et al. Restriction of T cell receptor Vβ repertoire in melanoma metastasis and response to immunotherapy. Melanoma Res 1995;5:129-132.
17. Willhauck M, Möhler T, Scheibenbogen C et al. T cell receptor β variable region diversity in melanoma metastases after rIL-2-based immunotherapy. Clinical Cancer Research 1996;2:767-772.
18. Herr W, Schneider J, Lohse AW et al. Detection and quantification of blood-derived CD8+T lymphocytes secreting tumor necrosis factor alpha in response to HLA-A2.1-binding melanoma and viral peptide antigens. J Immunol Methods 1996;191:131-142.
19. Scheibenbogen C, Lee K-H, Mayer S et al. A sensitive ELISPOT assay for detection of CD8+T-lymphocytes specific for HLA class I binding peptide epitopes derived from influenza proteins in the blood of healthy donors and melanoma patients. Clinical Cancer Research 1997;3:221-226.
20. Scheibenbogen C, Lee KH, Stevanovic S et al. Analysis of the T cell response to tumor and viral peptide antigens by an IFNg-ELISPOT assay. Int J Cancer 1997;71:932-936.
21. Marincola FM, Hijazi YM, Fetsch P et al. Analysis of expression of the melanoma-associated antigens MART-1 and gp100 in metastatic melanoma cell lines and in situ lesions. J Immunother Emphasis Tumor Immunol 1996;19:192-205.
22. Chen YT, Stockert E, Tsang S et al. Immunophenotyping of melanomas for tyrosinase: implications for vaccine development. Proc Natl Acad Sci U S A 1995;92:8125-8129.
23. Scheibenbogen C, Weyers I, Ruiter D et al. Expression of gp100 in melanoma metastases resected before or after treatment with IFNα and rIL-2. J Immunother Emphasis Tumor Immunol 1996;19: 375-380.
24. Lehmann F, Marchand M, Hainaut P et al. Differences in the antigens recognized by cytolytic T cells on two successive metastases of a melanoma patient are consistent with immune selection. Eur J Immunol 1995;25:340-347.
25. Restifo NP, Marincola FM, Kawakami Y et al. Loss of functional beta 2-microglobulin in metastatic melanomas from five patients receiving immunotherapy. J Natl Cancer Inst 1996;88: 100-108.
26. Scheibenbogen C, Keilholz U, Meuer S et al. Differential expression and release of LFA-3 and ICAM-1 in human melanoma cell lines. Int J Cancer 1993;54:494-498.
27. Brossart P, Schmier J, Krüger S et al. A polymerase chain reaction-based semiquantitative assessment of malignant melanoma cells in peripheral blood. Cancer Res 1995;55:4065-4068.
28. Kirkwood JM. Studies of interferons in the therapy of melanoma. Semin Oncol 1991;18:83-90.
29. Rosenberg SA, Lotze MT, Yang JC et al. Experience with the use of high dose interleukin-2 in die treatment of 652 cancer patients. Ann Surg 1989;210:474-485.
30. Thatcher N, Dazzi H, Gosh A et al. Recombinant rIL-2 given intra-splenically and intravenously in advanced malignant melanoma: a phase I/II study. Cancer Treat Rev 1989;16[suppl A]:49-52.
31. Parkinson DR, Abrams JS, Wiernik PH et al. Interleukin-2 therapy in patients with metastatic malignant melanoma: a phase II study. J Clin Oncol 1990;8[suppl A]:1650-1656.
32. Whitehead RP, Kopecky KJ, Samson MK et al. Phase II study of intravenous bolus recombinant interleukin-2 in advanced malignant melanoma: Southwest Oncology Group study. J Natl Cancer Inst 1991;83:1250-1252.
33. Dorval T, Mathiot C, Brandely M et al. Lack of effect of tumour infiltrating lymphocytes in patients with metastatic melanoma who failed to respond to interleukin 2 [correspondence]. Eur J Cancer 1991;27[suppl 2]:S99.
34. Sparano JA, Fisher RI, Sunderland M et al. Randomized phase III trial of treatment with high-dose interleukin-2 either alone or in combination with interferon-alfa-2a in patients with advanced melanoma. J Clin Oncol 1993;11:1969-1977.
35. Legha SS, Gianan MA, Plager C et al. Evaluation of interleukin-2 administered by continuous infusion in patients with metastatic melanoma. Cancer 1996;77:89-96.
36. Giacomini P, Aguzzi A, Pestka S et al. Modulation by recombinant DNA leukocyte (alpha) and fibroblast (beta) interferons of the expression and shedding of HLA- and tumor-associated antigens by human melanoma cells. J Immunol 1984;133:1649-1655.
37. Cameron RB, McIntosh JK, Rosenberg SA. Synergistic antitumor effects of combination immunotherapy with recombinant interleukin-2 and a recombinant hybrid alpha interferon in the treatment of established murine hepatic metastases. Cancer Res 1988; 48:5810-5817.
38. Rosenberg SA, Lotze MT, Yang JC et al. Combination therapy with interleukin-2 and alpha-interferon for the treatment of patients with advanced cancer. J Clin Oncol 1989;7:1863-1874.
39. Kruit WH, Goey SH, Monson JR et al. Clinical experience with the combined use of recombinant interleukin-2 (rIL-2) and interferon alpha-2a (IFN alpha) in metastatic melanoma. Br J Haematol 1991;79[suppl 1]:84-86.
40. Keilholz U, Scheibenbogen C, Tilgen W et al. Interferon-alpha and interleukin-2 in the treatment of malignant melanoma. Comparison of two phase II trials. Cancer 1993;72:607-614.
41. Dillman RO, Church C, Oldham RK et al. Inpatient continuous-infusion interleukin-2 in 788 patients with cancer: the National Biotherapy Study Group experience. Cancer 1993;71:2358-2370.
42. Marincola FM, White DE, Wise AP et al. Combination therapy with interferon alfa-2a and interleukin-2 for the treatment of metastatic cancer. J Clin Oncol 1995;5:1110-1122.
43. Kruit WHJ, Punt CJA, Goey SH et al. Dose efficacy study of two schedules of high-dose bolus administration of interleukin-2 and alpha-interferon in patients with metastatic melanoma. Br J Cancer 1996;74:951-955.
44. Keilholz U, Goey SH, Punt CJA et al. Interferon alfa-2a and interleukin-2 with or without cisplatin in metastatic melanoma: a randomized trial of the European Organization for Research and Treatment of Cancer Melanoma Cooperative Group. J Clin Oncol 1997;15:2579-2588.
45. Keilholz U, Scheibenbogen C, Sommer M et al. Prognostic factors for response and survival in patients with metastatic melanoma receiving immunotherapy. Melanoma Res 1996;6:173-178.
46. Rosenberg SA, Lotze MT, Muul LM et al. Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. N Engl J Med 1985;313:1485-1492.
47. Kruit WH, Punt CJA, Goey SH et al. Cardiotoxicity as a dose-limiting factor in a schedule of high dose bolus therapy with interleukin-2 and alpha-interferon: an unexpectedly frequent complication. Cancer 1994;74:2850-2856.
48. West WH, Tauer KW, Yanelli JR et al. Constant-infusion recombinant interleukin-2 in adoptive immunotherapy of advanced cancer. N Engl J Med 1987;316:898-905.
49. Stoter G, Shiloni E, Aamdal S et al. Sequential administration of recombinant human interleukin-2 and dacarbazine in metastatic melanoma: a multicentre phase II study. Eur J Cancer Clin Oncol 1989;25[suppl 3]:41-43.
50. Dillman RO, Oldham RK, Barth NM et al. Recombinant interleukin-2 and adoptive immunotherapy alternated with dacarbazine therapy in melanoma: a National Biotherapy Study Group trial. J Nad Cancer Inst 1990;82:1345-1349.
51. Flaherty LE, Redman BG, Chabot GG et al. A phase I-II study of dacarbazine in combination with outpatient interleukin-2 in metastatic malignant melanoma. Cancer 1990;65:2471-2477.
52. Demchak PA, Mier JW, Robert NJ et al. Interleukin-2 and high-dose cisplatin in patients with metastatic melanoma: a pilot study. J Clin Oncol 1991;9:1821-1830.
53. Flaherty LE, Robinson W, Redman BG et al. A phase II study of dacarbazine and cisplatin in combination with outpatient administered interleukin-2 in metastatic malignant melanoma. Cancer 1993;71:3520-3525.
54. Atkins MB, O'Boyle KR, Sosman JA et al. Multiinstitutional phase II trial of intensive combination chemotherapy for metastatic melanoma. J Clin Oncol 1994;12:1553-1560.
55. Dummer R, Gore ME, Hancock BW et al. A multi-center phase II clinical trial using dacarbazine and continuous infusion of interleukin-2 in metastatic melanoma. Clinical data and immunomonitoring. Cancer 1996;75:945-948.
56. Richards JM, Mehta N, Ramming K et al. Sequential chemoimmunotherapy in the treatment of metastatic melanoma. J Clin Oncol 1992;10:1338-1343.
57. Khayat D, Borel C, Tourani JM et al. Sequential chemoimmunotherapy with cisplatin, interleukin-2 and interferon alfa-2 for metastatic melanoma. J Clin Oncol 1993;11:2173-2180.
58. Buzaid AC, Legha SS. Combination of chemotherapy with interleukin-2 and interferon-alpha for the treatment of advanced melanoma. Semin Oncol 1994;6[suppl 14]:23-28.
59. Proebstle TM, Keilholz U, Scheibenbogen C et al. A phase II study of dacarbazine, cisplatin, interferon-alpha, and high-dose interleukin-2 in 'poor risk' metastatic melanoma. Eur J Cancer 1996; 32:1530-1533.
60. Redman BG, Flaherty L, Chou TH et al. Sequential dacarbazine/ cisplatin and interleukin-2 in metastatic melanoma: immunological effects of therapy. J Immunother 1991;10:147-151.
61. Keilholz U, Scheibenbogen C, Möhler T et al. Addition of dacarbazine or cisplatin to interferon-alpha/interleukin-2 in metastatic melanoma: toxicity and immunological effects. Melanoma Res 1995;5:283-287.
62. Keilholz U. Chemo-immunotherapy of melanoma: is it time for phase III trials? Cancer 1995;75:905-907.